Treatment for Mild Chronic Hypertension during Pregnancy

Alan Tita(The Centers), Jeff M. Szychowski(The Centers), Kim Boggess(University of North Carolina at Chapel Hill), Lorraine Dugoff(The Centers), Baha M. Sibai(The Centers), Kirsten Lawrence(The Centers), Brenna L. Hughes(Duke University), Joseph Bell(St. Luke's University Health Network), Kjersti M. Aagaard(Baylor College of Medicine), Rodney K. Edwards(The Centers), Kelly S. Gibson(MetroHealth), David M. Haas(The Centers), Lauren A. Plante(The Centers), Torri D. Metz(University of Utah), Brian M. Casey(The Centers), Sean Esplin(Intermountain Healthcare), Sherri Longo(Ochsner Baptist Medical Center), Matthew R. Hoffman(Christiana Care Health System), George R. Saade(The Centers), Kara K. Hoppe(Meriter Hospital), Janelle Foroutan(The Centers), Methodius G. Tuuli(Washington University in St. Louis), Michelle Owens(University of Mississippi Medical Center), Hyagriv N. Simhan(University of Pittsburgh), Heather A. Frey(The Centers), Todd Rosen(Rutgers, The State University of New Jersey), Anna Palatnik(Medical College of Wisconsin), Susan Baker(The Centers), Phyllis August(Cornell University), Uma M. Reddy(Yale University), Wendy Kinzler(Winthrop-University Hospital), Emily Su(University of Colorado Boulder), Iris Krishna(Emory University), Nicki Nguyen(Denver Health Medical Center), Mary E. Norton(San Francisco General Hospital), Daniel Skupski(New York Hospital Queens), Yasser Y. El‐Sayed(The Centers), Dotum Ogunyemi(Arrowhead Regional Medical Center), Zorina S. Galis(The Centers), Lorie M. Harper(The Centers), Namasivayam Ambalavanan(The Centers), Nancy L. Geller(Cancer Research And Biostatistics), Suzanne Oparil(University of Alabama at Birmingham), Gary Cutter(The Centers), William W. Andrews(The Centers)
New England Journal of Medicine
April 2, 2022
Cited by 516Open Access
Full Text

Abstract

BACKGROUND: The benefits and safety of the treatment of mild chronic hypertension (blood pressure, <160/100 mm Hg) during pregnancy are uncertain. Data are needed on whether a strategy of targeting a blood pressure of less than 140/90 mm Hg reduces the incidence of adverse pregnancy outcomes without compromising fetal growth. METHODS: In this open-label, multicenter, randomized trial, we assigned pregnant women with mild chronic hypertension and singleton fetuses at a gestational age of less than 23 weeks to receive antihypertensive medications recommended for use in pregnancy (active-treatment group) or to receive no such treatment unless severe hypertension (systolic pressure, ≥160 mm Hg; or diastolic pressure, ≥105 mm Hg) developed (control group). The primary outcome was a composite of preeclampsia with severe features, medically indicated preterm birth at less than 35 weeks' gestation, placental abruption, or fetal or neonatal death. The safety outcome was small-for-gestational-age birth weight below the 10th percentile for gestational age. Secondary outcomes included composites of serious neonatal or maternal complications, preeclampsia, and preterm birth. RESULTS: A total of 2408 women were enrolled in the trial. The incidence of a primary-outcome event was lower in the active-treatment group than in the control group (30.2% vs. 37.0%), for an adjusted risk ratio of 0.82 (95% confidence interval [CI], 0.74 to 0.92; P<0.001). The percentage of small-for-gestational-age birth weights below the 10th percentile was 11.2% in the active-treatment group and 10.4% in the control group (adjusted risk ratio, 1.04; 95% CI, 0.82 to 1.31; P = 0.76). The incidence of serious maternal complications was 2.1% and 2.8%, respectively (risk ratio, 0.75; 95% CI, 0.45 to 1.26), and the incidence of severe neonatal complications was 2.0% and 2.6% (risk ratio, 0.77; 95% CI, 0.45 to 1.30). The incidence of any preeclampsia in the two groups was 24.4% and 31.1%, respectively (risk ratio, 0.79; 95% CI, 0.69 to 0.89), and the incidence of preterm birth was 27.5% and 31.4% (risk ratio, 0.87; 95% CI, 0.77 to 0.99). CONCLUSIONS: In pregnant women with mild chronic hypertension, a strategy of targeting a blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension, with no increase in the risk of small-for-gestational-age birth weight. (Funded by the National Heart, Lung, and Blood Institute; CHAP ClinicalTrials.gov number, NCT02299414.).


Related Papers

No related papers found

Powered by citation graph analysis